Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer

BACKGROUND: Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Petra, Noonan, Sinead, Mullen, Michael P, Scaife, Caitriona, Tosetto, Miriam, Nolan, Blathnaid, Wynne, Kieran, Hyland, John, Sheahan, Kieran, Elia, Giuliano, O’Donoghue, Diarmuid, Fennelly, David, O’Sullivan, Jacintha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289341/
https://www.ncbi.nlm.nih.gov/pubmed/25428203
http://dx.doi.org/10.1186/1471-2407-14-887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289341/
https://www.ncbi.nlm.nih.gov/pubmed/25428203
http://dx.doi.org/10.1186/1471-2407-14-887

Ejemplares similares